1.Barre-Sinoussi, F et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871.
3.Maartens, G, Celum, C and Lewin, SR (2014) HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384, 258–271.
4.Berger, EA et al. (1998) A new classification for HIV-1. Nature 391, 240.
5.Berger, EA, Murphy, PM and Farber, JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annual Review of Immunology 17, 657–700.
6.Fatkenheuer, G et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine 11, 1170–1172.
7.Schuitemaker, H, van ‘t Wout, AB and Lusso, P (2011) Clinical significance of HIV-1 coreceptor usage. Journal of Translational Medicine 9(suppl. 1), S5.
8.Ghosn, J et al. (2017) CD4T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy 72, 2862.
9.Sierra-Enguita, R et al. (2014) X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. AIDS (London, England) 28, 1603.
10.Brumme, ZL et al. (2005) Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. The Journal of Infectious Diseases 192, 466–474.
11.Chalmet, K et al. (2012) Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. Journal of Infectious Diseases 205, 174.
12.Phuphuakrat, A et al. (2014) Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates. HIV Medicine 15, 269–275.
13.Li, X et al. (2014) Evidence that HIV-1 CRF01_AE is associated with low CD4 + T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China. PLoS ONE 9, e89462.
14.Tsai, HC et al. (2015) Chemokine co-receptor usage in HIV-1-infected treatment-naive voluntary counselling and testing clients in Southern Taiwan. BMJ Open 5, e007334.
15.Sabrina Wai-Chi, T et al. (2013) Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01_AE in Hong Kong by genotyping and phenotyping methods. Aids Research & Human Retroviruses 29, 1123–1128.
16.Hwang, SS et al. (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71–74.
17.Susan, ZP (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nature Reviews Immunology 4, 199.
18.Jiao, Y et al. (2014) HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naive MSM from 2011 to 2013 in Beijing, China. BMC Infectious Diseases 14, 689.
19.Vandekerckhove, LP et al. (2011) European guidelines on the clinical management of HIV-1 tropism testing. The Lancet Infectious Diseases 11, 394–407.
20.Cui, H et al. (2019) Rapid CD4 + T-cell decline is associated with coreceptor switch among MSM primarily infected with HIV-1 CRF01_AE in Northeast China. AIDS (London, England) 33, 13–22.
21.Li, Y et al. (2014) CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS (London, England) 28, 521.
23.Shepherd, JC et al. (2008) Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicentre AIDS cohort study. The Journal of Infectious Diseases 198, 1104–1112.
24.Richman, DD and Bozzette, SA (1994) The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. Journal of Infectious Diseases 169, 968–974.
25.Tersmette, M et al. (1988) Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Journal of Virology 62, 2026–2032.
26.Panos, G and Watson, DC (2014) Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition. Critical Reviews in Microbiology 41, 473.
27.Tsuchiya, K et al. (2013) Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism. Scientific Reports 3, 2389.
28.Clevestig, P et al. (2006) CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. Journal of General Virology 87, 607–612.
29.Polzer, S et al. (2002) The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304, 70–80.
30.Milich, L, Margolin, BH and Swanstrom, R (1997) Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology 239, 108–118.
31.Coetzer, M et al. (2006) Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 356, 95–105.